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(95% CI: 0.21, 0.43) and 0.46 (95% CI: 0.37, 0.54) prior to and
after Feb 2010, respectively (P¼ .11). Eighty-six patients
(44%) were considered at high risk for IFI pre-HSCT by
standard criteria. The rate of IFI post HCT was 9/69 (13%)
and 18/127 (14%) prior to and after Feb 2010, respectively.
Proven (n¼2) or probable (n¼2) IFI was only observed in 4
patients (2%), with the remainder having possible IFI.
Subgroup analysis did not ﬁnd any statistical difference
between the two groups for aGVHD analyzed by stem cell
source or IFI analyzed by pre-HSCT risk. In addition, there
was no difference in the number of dose modiﬁcations
required and when patients were analyzed by actual day of
azole start.
Conclusion: Delaying the start of triazole prophylaxis till 7
days after allo-HSCT does not affect outcomes, including
achieving and maintaining therapeutic levels of GVHD
prophylaxis, and incidence of aGVHD or IFI.543
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Cardiac arrhythmias (CA) can be an important complica-
tion of cellular therapy. We performed a retrospective,
single center, comprehensive analysis to understand the
risk factors, outcome and morbidity of cardiac arrhyth-
mias developing in the ﬁrst 100 days after allogeneic
hematopoietic stem cell transplantation in adults. Overall
133 patients received an allogeneic transplant between
01/2008 and 07/2012 and were included in the analysis.
Individuals with pre existing arrhythmias were excluded.
Patients and transplant characteristics are detailed in
Table 1. At least one episode of cardiac arrhythmiaTable 1
Demographics N¼133
Median age (range) 54 (18-70)
Male gender 85 (64%)
Race
African American 25 (19%)
Caucasian 107 (80%)
Other 1 (1%)
Diagnosis
Acute Leukemias 75 (56%)
MDS 20 (15%)
Lymphomas 19 (14%)
CML 11 (8%)
CLL/PLL 5 (4%)
MM 2 (2%)
AA 1 (1%)
Graft source
Adult MUD/MMUD 78 (59%)
Sibling 47 (35%)
Haploidentical family 3 (2%)
Cord blood 5 (4%)
Conditioning
Myeloablative 48 (36%)
RIC/NMA 85 (64%)
Comorbidities
Median left ventricle ejection fraction (range) 60% (33-76)
Hypertension 47 (35%)
Diabetes 26 (20%)
Coronary artery disease 5 (4%)
Smoking history 69 (52%)developed in 25 individuals (18.8%, 95% C.I. 13.0-26.3%)
with 19 individuals developing atrial ﬂutter/ﬁbrillation
and 8 individuals developing AV nodal reentrant tachy-
cardia. Median time of onset of the arrhythmia was 27
days (range 1-96) after transplant. Neither underlying
disease, conditioning regimen, comorbidities, left
ventricular ejection fraction, presence of ventricular dia-
stolic dysfunction, prior use of beta blockers, calcium
channel blockers, ACE inhibitors or ARBs were associated
with higher risk of developing CA in univariate or multi-
variate analysis. Patients who developed CA were older
(median age 56 years) than patients who did not develop
CA (median age 51 years), but this difference was not
statistically signiﬁcant (P ¼ .08). Of the 25 individuals who
developed CA, 13 died prior to day 100 (4 from cardiac
causes). Among the remaining 12 patients, 8 had resto-
ration of sinus rhythm by day 100. Median survival was
14+/- 2 weeks for individuals who developed CA vs. 81 +/-
35 weeks for patients who did not develop CA prior to 100
days (P < .0001). In multivariate analysis, development of
CA prior to 100 days was a strong predictor of mortality
(HR¼2.87, 95% C.I. 1.67-4.95, P ¼ .001) even when adjusted
for age, intensity of the conditioning regimen, comorbid-
ities, chronic medications, left ventricular ejection fraction
and presence of ventricular diastolic dysfunction. We
concluded that the development of CA after allogeneic
transplantation is relatively common, but difﬁcult to
predict on the basis of patient and transplant character-
istics, representing a strong and independent predictor of
post transplant mortality.
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Allogeneic bone marrow transplant (BMT) patients with
cyclosporine-induced hypertension are at risk of serious
complications including intracerebral hemorrhage and
seizures. There is little data describing cyclosporine-
induced hypertension in the allogeneic BMT population.
The aim of this study was to characterize cyclosporine-
induced hypertension in the allogeneic BMT population at
the Medical University of South Carolina (MUSC), while
also investigating what blood pressure (BP) medications
currently used may be most efﬁcacious. We conducted
a single center, IRB approved, retrospective study of
patients receiving an allogeneic BMT from January 1, 2008
to August 31, 2011. Demographic data was collected for all
patients. Those patients experiencing cyclosporine-
induced hypertension had additional data recorded:
number of systolic blood pressure (SBP) readings > 160
mmHG, number of diastolic blood pressure (DBP) readings
>100 mmHg, addition of an antihypertensive medication,
and number of doses and dosage administered. Safety was
assessed through recording number of SBP readings < 100
mmHG, number of DBP readings < 40 mmHg, and the
minimum heart rate (HR) while on cyclosporine. Twenty
seven (27) of 78 patients were identiﬁed as experiencing
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received treatment with amlodipine while 14 received
treatment with other antihypertensives, primarily beta
blockers (n¼11). A signiﬁcant difference was not found in
the primary or secondary endpoints, which assessed safety
and efﬁcacy between the treatment groups. Signiﬁcant
differences were found between those with and those
without cyclosporine-induced hypertension. Patients with
cyclosporine-induced hypertension had a longer mean
length of stay, 35.4 days (18-109) as compared to 24.1 days
(7-74). Zero of the 9 patients who received amlodipine
prior to and during the BMT admission went on to expe-
rience cyclosporine-induced hypertension. Available
results, although not robust, suggest that safety and efﬁ-
cacy are similar in allogeneic BMT patients whether they
receive amlodipine or another antihypertensive to treat
cyclosporine-induced hypertension. However, the data
provided did identify that those patients receiving amlo-
dipine prior to and during their bone marrow transplant
were less likely to experience cyclosporine-induced
hypertension.545
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Background: Peri-transplant iron overload (IOL) has been
associated with increased non-relapse morbidity and
mortality in patients receiving hematopoietic stem cell
transplant (HSCT). Iron chelation therapy (ICT) with
deferoxamine or deferasirox, and phlebotomy remain the
major therapeutic options for reducing IOL in HSCT recip-
ients, though the role of ICT in these patients, particularly
in the post-transplant period, has not been clearly deﬁned.
The aim of this study was to evaluate the impact of
post-transplant ICT on outcomes up to day +100 in allo-
geneic HSCT, and to assess the tolerability of post-trans-
plant ICT.
Methods: A retrospective medical record review of 29
patients who underwent allogeneic HSCT from March 2009
to October 2011 at a 779-licensed bed, urban academic
medical center was conducted. Inclusion criteria were age 
18 years and serum ferritin level  1000 ng/mL within 3
months prior to transplant. Exclusion criteria were mis-
matched or cord blood transplant, and ICT initiated in the
pre-transplant period or after day +50. Patients were divided
into 2 groups: those who received  1 dose of deferoxamine
or deferasirox post-transplant up to day +50 (ICT group), and
those who had never received ICT (non-ICT group). The
primary endpoint was clinically signiﬁcant liver dysfunction
up to day +100.
Results: Of the 29 patients evaluated, 22 were in the non-
ICT group and 7 in the ICT group (6 received deferoxamine
1000 mg IV daily, 1 received deferasirox 2000 mg orally
daily; median duration of ICT, 24 days). There were no
statistically signiﬁcant differences between the groups in
demographic or transplant characteristics, though there
was a longer median time from diagnosis to transplant
(417 vs. 238 days, P ¼ .37) and a higher median pre-
transplant ferritin level (2910 vs. 1673 ng/mL, P ¼ .38) in
the ICT group compared to the non-ICT group. Four
patients experienced clinically signiﬁcant liver dysfunc-
tion, with 3 patients (13.6%) in the non-ICT group and 1patient (14.3%) in the ICT group (P ¼ .99). There were no
signiﬁcant differences in other post-transplant outcomes
evaluated, including change in ferritin level, bloodstream
infection, and death. Of the 7 ICT patients, 71.4% experi-
enced acute kidney injury that required interruption or
discontinuation of ICT.
Conclusions: ICT in the immediate post-transplant period
did not improve post-transplant outcomes and was not well
tolerated. Alternative strategies for the administration of
pre- or peri-transplant ICT in HSCT recipients are recom-
mended.546
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Background: Linezolid (LZ) is an oxazolidinone antimicro-
bial often used to treat resistant gram-positive bacteria and
has been associated with mild, reversible, time-dependent
myelosuppression, including thrombocytopenia (common),
anemia (common), leukopenia, and pancytopenia. Gener-
ally, these effects occur with treatment durations of  14
days. Patients with underlying hematologic abnormalities
may be more at risk for the development of LZ-induced
myelosuppression, but this is controversial. We hypothe-
sized that LZ use before engraftment may delay hemato-
poietic recovery following stem cell transplant (SCT), and
performed a matched controlled analysis to investigate this
hypothesis.
Methods: With institutional review board approval, we
retrospectively evaluated 24 patients who received LZ and
compared them to 60 controls who did not receive LZ from 1/
1/1997 to 1/1/2010. Our SCT database was utilized to ﬁnd
matched controls and matching was based on: diagnosis;
transplant type; cell source; transplant conditioning
regimen; and age +/- 10 years. Patients in the LZ group were
included if LZ was administered at any time from day
0 through engraftment of white cells but for a minimum of
72 consecutive hours. Patients 1 year of age or older were
included. The datawere analyzed for the effects of LZ on time
to neutrophil (ANC > 500 for 3 days) and platelet engraft-
ment (platelet count > 20,000 for 7 days without trans-
fusion), and the cumulative incidence of engraftment of both
neutrophil and platelets within the ﬁrst 100 days post-
transplant.
Results: The LZ and control groups were similar with
respect to age (median 44 vs. 41 years), gender (50% vs. 58%
male and 50% vs. 42% female), diagnosis (29% vs. 25% had
AML/MDS), cell source (67% vs. 63% apheresis product),
transplant type (67% vs. 63% allogeneic), ablative vs. non-
ablative conditioning (79% vs. 83% myeloablative), and cell
dose (median CD34 dose 4.52 x 106/kg vs. 4.34 x 106/kg).
Median time to neutrophil engraftment was the same for LZ
and control groups (12 days). The median time to neutro-
phil plus platelet engraftment for LZ group and control
group was 50 days (11 patients censored) vs. 15.5 days (10
patients censored). Neutrophil engraftment failure occurred
